<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4960">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042364</url>
  </required_header>
  <id_info>
    <org_study_id>Miacol-2017-3H</org_study_id>
    <nct_id>NCT03042364</nct_id>
  </id_info>
  <brief_title>Cytokine Profile of the Uterine Secretome After Therapeutic Endometrial Scratching</brief_title>
  <official_title>Cytokine Profile of the Uterine Secretome After Therapeutic Endometrial Scratching</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the impact of endometrial scratching on endometrial secretion, when
      correlated to pregnancy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized clinical trial</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine profile of the uterine secretome after therapeutic endometrial scratching</measure>
    <time_frame>Within 12 months</time_frame>
    <description>The secretome is analyzed using a Multiplex analysis with 45 cytokines, chemokines and growth factors from ProcartaPlex Immunoassay Kit, Affymetrix, eBioscience. The samples are normalized for total protein content using a Nanodrop spectrophometer, and the protein composition is further determined by sodium dodecyl sulphate-polyacrylamide gel electropheresis (SDS-PAGE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunoassay Kit:</measure>
    <time_frame>Within 12 months</time_frame>
    <description>BDNF, EGF, Eotaxin, FGF-2, GMCSF, GRO-alpha, HGF, IFN alpha, IFN gamma, IL-1RA, IL-1alpha, IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL17-A, IL-18, IL-21, IL-22, IL-23, IL-27, IL-31, IP-10, LIF, MCP-1, MIP-1 alpha, MIP-1 beta, NGF beta, RANTES, PDGF-BB, PÅIGF-1, SCF, SDF-1 alpha, TNF alpha, TNF beta, VEGF-A, VEGF-D</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endometrial scratching before standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pipelle de Cornier</intervention_name>
    <description>RCT with endometrial scratching prior to hormone treatment in ART. Aspiration of uterine secretion at transfer day</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IVF or ICSI patients with ≥1 previous implantation failure, despite transfer of a top
             quality embryo or blastocyst.

          -  Antagonist treatment

          -  FSH: 2-12 IU/L

          -  BMI: 18-32

          -  Regular menstrual cycle

          -  Written consent

        Exclusion Criteria:

          -  Suspected intrauterine abnormalities Planned use of specialized media or AHA
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fertility Clinic,Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tine Hansen, MD</last_name>
      <email>tnh@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fertility Clinic, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Louise Groendahl</last_name>
      <email>Marie.Louise.Groendahl@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fertility Clinic Horsens Hospital</name>
      <address>
        <city>Horsens</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mia Steengaard Olesen, MD</last_name>
      <email>miaolsen@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Inge Agerholm, M.Sc., ph.D.</last_name>
      <email>inge.e.agerholm@horsens.rm.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Mia Steengaard Olesen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fertility Clinic, Skive Hospital</name>
      <address>
        <city>Skive</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Humaidan, DMSc</last_name>
      <email>peter.humaidan.@viborg.rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>January 31, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrium, Cytokines, Endometrial secretion, Implantation, Endometrial scratching</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
